PTC Therapeutics Inc.'s plans to appeal a US FDA complete response letter for Translarna (ataluren) could once again make Center for Drug Evaluation and Research (CDER) Director Janet Woodcock the decision-maker on a Duchenne muscular dystrophy drug that the agency's own clinical reviewers have concluded lacks substantial evidence of efficacy.
On Oct
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?